CAR T-cell therapy is an innovative form of immunotherapy that is finding increasing use for the management of blood cancers. While this approach has demonstrated impressive results for some patients, there are still challenges such as toxicity and difficulty in predicting which patients will respond.
The immune microenvironment is one of the factors that influences clinical outcomes, so identifying immune biomarkers is critical to maximizing the benefits of CAR T-cell therapy.
During this webinar, Adrian Bot, Vice President of Translational Medicine at Kite, a Gilead Company, will explain how biomarker evaluation for CAR T-cell therapy can elucidate the mechanism of action and impact drug development.
This webinar will also include a brief overview of HalioDx's Immunogram platform and how it can provide meaningful and actionable data through biomarker testing.
Attendees of this webinar will learn:
- How CAR T-cell therapy fights cancer cells and the associated mechanism of action.
- Why evaluating immune biomarkers in CAR T-cells is crucial.
- How biomarker evaluation can impact immunotherapy drug development.